# Basic and Translational Science CR0I2023

jmpicado@irsicaixa.es











The year of the "single-cell"


#### Oral Abstract Session-05 HIV RESERVOIRS AND CURE STRATEGIES #135


**SINGLE-CELL PROTEOGENOMIC PROFILING OF HIV-1 RESERVOIR CELLS Weiwei Sun**<sup>1</sup>, Ce Gao<sup>1</sup>, Ciputra A. Hartana<sup>1</sup>, Matthew R. Osborn<sup>1</sup>, Kevin B. Einkauf<sup>1</sup>, Xiaodong Lian<sup>1</sup>, Benjamin R. Bone<sup>1</sup>, Nathalie Bonheur<sup>1</sup>, Tae-Wook Chun<sup>2</sup>, Eric S. Rosenberg<sup>3</sup>, Bruce D. Walker<sup>1</sup>, Xu G. Yu<sup>1</sup>, Mathias Lichterfeld<sup>1</sup> *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA, <sup>2</sup>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA, <sup>3</sup>Massachusetts General Hospital, Cambridge, MA, USA* 

┻


## Phenotyping and Proviral Sequencing (PheP-Seq)

Simultaneous detection of HIV-1 proviral sequence and surface phenotype at the single-cell level







## Distinc phenoty



**Blood Cel** 





5

#### Conclusions

- PheP-Seq is capable of profiling the phenotypic features of <u>single HIV-1-infected cells</u> *ex-vivo*
- No major phenotypic differences between HIV-1-infected (defective) and non-infected cells
- After ~10 years of ART, cells harboring intact proviruses are enriched for <u>negative</u> <u>immunoregulatory</u> markers and <u>immune checkpoint</u> markers
- This phenotype may help reservoir cells with intact HIV-1 to <u>avoid</u> being exposed to and killed by host immune cells
- Data suggest that only HIV-1-infected cells with <u>optimal adaptation</u> to host immune activity or their specific tissue microenvironment can <u>survice long term</u>
- → Reservoir cells with intact HIV are subject to active immune selection pressure





Illuminating a long-term mystery

**Oral Abstract Session-01 VIROLOGY/PATHOGENESIS** 


#105

# HOST CELL GLYCOSYLATION DIFFERENTIALLY AFFECTS CCR5- AND CXCR4-TROPIC HIV-1 INFECTION

#### Hannah L. Itell<sup>1</sup>, Julie M. Overbaugh<sup>2</sup>

<sup>1</sup>*Fred Hutchinson Cancer Research Center, Seattle, WA, USA, <sup>2</sup>University of Washington, Seattle, WA, USA* 

#### R5-tropic HIV bottleneck during transmission




Longstanding question in the HIV field:

What are the viral and host properties that drive preferential transmission of CCR5-tropic viruses?

#### SLC35A2 is associated with R5-tropic infection


CRISPR KO screen for HIV restriction factors comparing R5-tropic vs. X4-tropic HIV

SLC35A2 KO has consistent, opposite effects on X4 vs. R5 HIV (primary CD4+ cells)



SLC35A2 encodes a transporter of UDP-galactose whose inactivation causes truncated glycans

Wildtype Glycosylation




### SLC35A2 is more highly expressed in the lower Female Reproductive Tract than in blood



Bulk RNA-seq on CD4<sup>+</sup> T Cells Matched sample types for 4 donors Davis et al., 2021 *Mucosal Immunol* 

SLC35A2 Expression in CD4+ T cells



Increased SLC35A2 - Increased glycosylation - R5 selection at transmission sites

#### Conclusions

- Underappreciated role for <u>host cell glycans</u> on the infection of different tropic-HIV strains
- Wildtype <u>glycosylation promotes R5 infection</u> while hindering that of X4
- Putative role of <u>SLC35A2</u>, a gene required for normal glycosylation, which encodes a transporter of <u>UDP-galactose</u>. Its inactivation causes truncated glycans.
- Wildtype glycosylation may be even more pronounced in the <u>genital tract</u> due to elevated levels of SLC35A2, contributing to R5 selection at transmission sites

 $\rightarrow$  The differential impact of host cell glycosylation on X4 and R5 viruses may therefore largely drive R5 selection during HIV transmission.



Gene/Cell Therapies


# Oral Abstract Session-10 IMMUNOPATHOGENESIS AND VACCINES #182

#### SINGLE INFUSION OF STEM LIKE CCR5-MODIFIED CD4 T CELLS PROVIDE LONG-TERM HIV CONTROL


**Ana B. Enriquez**<sup>1</sup>, Ashish Arunkumar Sharma<sup>1</sup>, Joumana Zeidan<sup>2</sup>, Gary Lee<sup>3</sup>, Slim Fourati<sup>1</sup>, Khader Ghneim<sup>1</sup>, Gabriela Sanchez<sup>1</sup>, Francesco Procopio<sup>4</sup>, Robert Balderas<sup>5</sup>, Nicolas Chomont<sup>6</sup>, Dale Ando<sup>7</sup>, Steven G. Deeks<sup>8</sup>, Rafick P. Sékaly<sup>1</sup>, Rémi Fromentin<sup>9</sup>

<sup>1</sup>Emory University, Atlanta, GA, USA, <sup>2</sup>CellCarta, Montreal, QC, Canada, <sup>3</sup>Senti Biosciences, San Francisco, CA, USA, <sup>4</sup>Lausanne University Hospital, Lausanne, Switzerland, <sup>5</sup>BD Biosciences, San Diego, CA, USA, <sup>6</sup>Université de Montréal, Montréal, Canada, <sup>7</sup>Consultant, Walnut Creek, CA, USA, <sup>8</sup>University of California San Francisco, San Francisco, CA, USA, <sup>9</sup>Centre de Recherche du CHUM, Montreal, QC, Canada 5

#### Autologous CCR5-modified T cells




# RORA cells are distinct from conventional T stem cell memory subsets



### Conclusions

- Single infusion of CCR5-modified T cells enriches a novel RORA CD4 T cell population:
  - Have a <u>stem-like phenotype</u> (innately more "quiescent")
  - Correlate with <u>CCR5-modified</u> T cells
  - Can differentiate into <u>effector</u> cells that correlate with reduced viral load and effector CD8 T cells (in absence of ART)
  - Confer long-term HIV protection










#### PLENARY-03 WEDNESDAY PLENARY SESSION

#037

#### HOW THE HUSH COMPLEX PROTECTS YOUR GENOME FROM RNA-DERIVED RETROELEMENTS Paul J. Lehner Cambridge University, Cambridge, United Kingdom

#### Retrotransposition


- Reverse Transcriptase: RNA  $\rightarrow$  cDNA  $\rightarrow$  subsequent genome integration
- 40% of the human genome are retroelements (retroviruses/ retrotransposons)
- Retrotransposition is therefore tolerated, but needs to be closely regulated



- 'HUSH' (Human Silencing Hub): epigenetic transcriptional repressor complex which identifies and silences invading transgenes
  - It defends the genome from retroelement attack from outside the cell i.e. retroviruses (including HIV) and from within the cell (LINE1 retrotransposons)

## How does HUSH discriminate 'self' from 'non-self' genomic DNA?

- HUSH recognizes 'intronless' DNA  $\rightarrow$  retroelements lack non-coding introns acting (~PAMPs)
- cDNA >  $\sim$ 1.5Kb, rich in adenine, and transcriptionally active



## **Biological relevance**

- Novel component of the <u>innate immunosystem</u> → immunosurveillance of the genome, a compartment not thought to be accessible to the immune system (no cell killing!)
- Major <u>therapeutic</u> potential (beyond fundamental biological importance):
  - Strategies to express genes for a wide range of purposes have, somewhat unwittingly, been a battle against HUSH
  - HUSH inhibition has the potential to dramatically improve gene expression, and to release neo-antigens for cytotoxic T-lymphocyte recognition for immunotherapy
  - HIV?
    - Elite controllers
    - Long-term ART

MIMI ©

Intact HIV genome integrated in repressed/non-accessible genomic regions

Enrichment of the repressive histone feature H3K9me3 at intact-HIV integration sites

Clonal expansion of cells with intact HIV-1 integrated in heterochromatin regions

Jiang *et al.* Nature 2020 Lian *et al.* Cell Host and Microbes 2023

#### Conclusions

- HUSH → epigenetic transcriptional repressor complex which silences invading DNA
- HUSH defends the genome from <u>retroelement attack</u> from outside the cell i.e. retroviruses (including HIV) and from within the cell (LINE1 retrotransposons)
- Unique RNA-dependent genome surveillance system linking transcription to epigenetic gene silencing, by recognizing <u>'intronless' DNA</u>
- Major <u>therapeutic</u> potential: improve gene expression to release neo-antigens for cytotoxic Tlymphocyte recognition for immunotherapy, and maybe HIV ...
- → HUSH: "Molecular domestication" of retroviruses and retrotransposons



Bonys

Brief Communication

https://doi.org/10.1038/s41591-023-02213-x

In-depth virological and immunological characterization of HIV-1 cure after CCR5 $\Delta$ 32/ $\Delta$ 32 allogeneic hematopoietic stem cell transplantation

#434 HIV-1 Host Reservoir Reactivation after a CCR5A32/32 Allogeneic Stem Cell Transplant

- AML; 10/10 match, CCR5∆32
- Rapid full donor chimerism (in peripheral blood)
- Decrease in cell-associated DNA and RNA
- Decrease in ultrasensitive plasma viral load
- Rebounding viruses are CCR5-tropic
  - Residual R5-tropic HIV can persist in vivo even >1 year after SCT
  - Non clonal reactivation
- No increase in plasma HIV-associated antibodies
- No evidence of graft infection to date
- No data on tissues

